Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 49Tumor-Agnostic 3Lymphoid 2Thoracic 1NET 1Endocrine 1

Conditions

Vipoma 1Somatostatinoma 1Neuroendocrine Tumors 1Neoplasms 1Lung Neoplasms 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Everolimus 2lutetium Lu 177 dotatate 1Somatostatin 1Sirolimus 1Positron Emission Tomography Computed Tomography 1Oxaliplatin 1Leucovorin 1Injections 1Fluorouracil 1Bevacizumab 1Axitinib 1Al18F-NOTA-octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Oxaliplatin × NET × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡